No Access
Sponsored by
The University of Chicago Booth School
of Business and The University of Chicago Law School
Article DOI
https://doi.org/10.1086/467258
Views: 10
Total views on this site
Total views on this site
Citations: 20
Citations are reported from Crossref
Citations are reported from Crossref
Copyright 1992 The University of Chicago
Crossref reports the following articles citing this article:
Casey B. Mulligan Peltzman Revisited: Quantifying 21st-Century Opportunity Costs of Food and Drug Administration Regulation,The Journal of Law and Economics 65, no.S2S2 (Mar 2023): S355–S387.Casey B. Mulligan Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation,SSRN Electronic Journal 119 (Jan 2021).Hoe Sang Chung, Min Kim The price effect of allowing non-pharmacy outlets to sell OTC drugs in Korea,Applied Economics Letters 25, no.1818 (Dec 2017): 1316–1318.Monica Hildegard Otto, Carla Pillarella, Claudio Jommi The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy,Frontiers in Pharmacology 9 (Oct 2018).Joshua Noone, Christopher M. Blanchette The value of self-medication: summary of existing evidence,Journal of Medical Economics 21, no.22 (Nov 2017): 201–211.Natalie J. Gauld, Fiona S. Kelly, Nahoko Kurosawa, Linda J. M. Bryant, Lynne M. Emmerton, Stephen A. Buetow, Meijia Zhang Widening Consumer Access to Medicines through Switching Medicines to Non-Prescription: A Six Country Comparison,PLoS ONE 9, no.99 (Sep 2014): e107726.Richard P. Rozek Switching Pharmaceutical Products from Prescription to Over-the-Counter: The Debate in the U.S.,European Journal of Risk Regulation 3, no.44 (Jan 2017): 601–607.E P Brass, R Lofstedt, O Renn Improving the Decision-Making Process for Nonprescription Drugs: A Framework for Benefit–Risk Assessment,Clinical Pharmacology & Therapeutics 90, no.66 (Nov 2011): 791–803.L. Douglas Ried, Sally A. Huston, Suzan N. Kucukarslan, Elliott M. Sogol, Kenneth W. Schafermeyer, Sujit S. Sansgiry Risks, benefits, and issues in creating a behind-the-counter category of medications,Journal of the American Pharmacists Association 51, no.11 (Jan 2011): 26–39.Gila E. Fruchter, Murali K. Mantrala Proactive Planning of the Timing of a Partial Switch of a Prescription to Over-the-Counter Drug,Production and Operations Management 19, no.55 (Aug 2010): 614–628.Davina C. Ling , Ernst R. Berndt , and Margaret K. Kyle Deregulating Direct‐to‐Consumer Marketing of Prescription Drugs: Effects on Prescription and Over‐the‐Counter Product Sales Ling/Berndt/Kyle,The Journal of Law and Economics 45, no.S2S2 (Jul 2015): 691–723.Theodore E. Keeler, Teh‐wei Hu, Alison Keith, Richard Manning, Martin D. Marciniak, Michael Ong, Hai‐Yen Sung The benefits of switching smoking cessation drugs to over‐the‐counter status,Health Economics 11, no.55 (Jan 2002): 389–402.Lars Noah Challenges in the Federal Regulation of Pain Management Technologies,SSRN Electronic Journal (Jan 2002).Albert A. Okunade The Impact of 1990 Medicaid Drug Rebates Policy on Access to Prescriptions,Journal of Health & Social Policy 12, no.33 (Oct 2008): 33–51.Françoise G Pradel, Abraham G Hartzema, Elizabeth J Mutran, Christine Hanson-Divers Physician Over-the-Counter Drug Prescribing Patterns: An Analysis of the National Ambulatory Medical Care Survey,Annals of Pharmacotherapy 33, no.44 (Jun 2016): 400–405.R.William Soller Evolution of self-care with over-the-counter medications,Clinical Therapeutics 20 (Jan 1998): C134–C140.Anthony M. Marino Regulation of product safety design through product testing,Journal of Regulatory Economics 7, no.33 (May 1995): 255–276.
